ArticleFrontiers in toxicology2025
Epidemiological investigation of venomous snakebites in Yunnan Province.
Article in Frontiers in toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Toxicological profiling of venoms from ten major Chinese snakes: a mass spectrometry-based proteomic and multiroute assessment.Archives of toxicology · 2026Article
- Fibrinogen supplementation enhances antivenom efficacy in treating coagulopathy due to hemotoxic snakebite envenoming byFrontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Snakebite envenoming constitutes a substantial public health concern worldwide. Yunnan Province, The lack of comprehensive epidemiological data on snakebite in Yunnan affects research, diagnostic, and treatment advancements. This research evaluates patient demographics, seasonal patterns, snake species associated with the disease, and treatment approaches to guide preventative and therapeutic initiatives in the province. Methods: This retrospective analysis reviewed clinical records of venomous snakebite cases admitted to hospitals in 16 cities within Yunnan Province from January 2022 to November 2024. Collected data covered diverse aspects, including patient demographics (age, sex), circumstances of the bite (location, size, and time), species identification, observed clinical symptoms, treatments administered (e.g., antivenin and alternative therapies), and hospital stay duration. Subsequently, the effect of different therapeutic measures on these patients' hospital stays was analyzed. Results: A total of 2,112 venomous snakebite cases were recorded, with incidence rates rising annually: 406/46.73 million in 2022, 825/46.73 million in 2023, and 886/46.73 million in 2024. Conclusion: Snake bites in Yunnan Province mainly affect young and middle-aged agricultural workers in rural and mountainous areas. The predominant venomous snakes in the area are hemotoxic. The findings emphasize the necessity of early intervention with antivenom and adjunctive therapies, including fibrinogen and plasma administration. Delays in getting medical help or improper treatment can lead to longer hospital stays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.